Definition of Ustekinumab. Meaning of Ustekinumab. Synonyms of Ustekinumab

Here you will find one or more explanations in English for the word Ustekinumab. Also in the bottom left of the page several parts of wikipedia pages related to the word Ustekinumab and, of course, Ustekinumab synonyms and on the right images related to the word Ustekinumab.

Definition of Ustekinumab

No result for Ustekinumab. Showing similar results...

Meaning of Ustekinumab from wikipedia

- Ustekinumab, sold under the brand name Stelara among others, is a monoclonal antibody medication developed by Janssen Pharmaceuticals, for the treatment...
- program comprising four clinical trials which compared risankizumab to ustekinumab, adalimumab and placebo in the indication of plaque psoriasis. The results...
- treatment with ustekinumab. It showed that patients who switched to guselkumab from ustekinumab did better than those who remained on ustekinumab. "Tremfya...
- received marketing authorization in 2021, and its second product, an ustekinumab biosimilar, in 2023. Products under development include biosimilars of...
- bimekizumab is superior to not only adalimumab but also secukinumab and ustekinumab for the treatment of plaque psoriasis. "Bimzelx APMDS". Therapeutic Goods...
- needed] Ustekinumab (CNTO 1275) is a monoclonal antibody that suppresses cytokines IL-12 and IL-23. Originally designed to treat psoriasis, ustekinumab was...
- such as vedolizumab and natalizumab and interleukin antagonists like ustekinumab. Prior to the development of biological therapy as a modality to treat...
- share a common domain, p40, which is the target of the FDA-approved ustekinumab. In 2017 the US FDA approved guselkumab for plaque psoriasis. There have...
- Armando; Moreira, Ana Isabel (2016-05-24). "Inverse psoriasis treated with ustekinumab". BMJ Case Reports. BMJ: bcr2016215019. doi:10.1136/bcr-2016-215019....
- development for psoriasis has been discontinued in the U.S. and Europe. Like ustekinumab, the antibody targets the interleukins 12 and 23. The candidate drug...